Investing.com -- SELLAS Life Sciences Group (NASDAQ:SLS) shares surged 240% after the company announced positive topline results from its pivotal Phase 3 REGAL trial of galinpepimut-S (GPS), an immunotherapeutic cancer vaccine for acute myeloid leukemia.
The REGAL trial met its primary endpoint of overall survival, with GPS demonstrating a 41% reduction in the risk of death compared to best available treatment. The trial showed a median overall survival of 24.0 months for GPS-treated patients versus 14.7 months for the control group, with a hazard ratio of 0.59 and a two-sided p-value of 0.035.
The trial evaluated GPS as maintenance monotherapy in patients with acute myeloid leukemia who achieved a second or later complete remission following second- or later-line salvage therapy and who were ineligible for, or unable to undergo, allogeneic stem cell transplantation.
GPS was generally well tolerated, with a safety profile consistent with prior clinical experience and no new safety signals identified.…